Share This Article

Facebook LinkedIn
Twitter Reddit
Print Email
Pinterest Gmail
Yahoo
Money Morning
×
  • Invest
    • Best Stocks to Buy
    • Stock Forecasts
    • Stocks to Sell Now
    • Stock Market Predictions
    • Technology Stocks
    • Best REITs to Buy Now
    • IPO Stocks
    • Penny Stocks
    • Dividend Stocks
    • Cryptocurrencies
    • Cannabis Investing
    • Angel Investing
  • Trade
    • How to Trade Options
    • Best Trades to Make Now
    • Options Trading Strategies
    • Weekly Trade Recommendations
  • Retire
    • Income Investing Guide
    • Retirement Articles
  • More
    • Money Morning LIVE
    • Special Investing Reports
    • Our ELetters
    • Our Premium Services
    • Videos
    • Meet Our Experts
    • Profit Academy
Login My Member Benefits Archives Research Your Team About Us FAQ
  • Invest
    • Best Stocks to Buy
    • Stock Forecasts
    • Stocks to Sell Now
    • Stock Market Predictions
    • Technology Stocks
    • Best REITs to Buy Now
    • IPO Stocks
    • Penny Stocks
    • Dividend Stocks
    • Cryptocurrencies
    • Cannabis Investing
    • Angel Investing
    ×
  • Trade
    • How to Trade Options
    • Best Trades to Make Now
    • Options Trading Strategies
    • Weekly Trade Recommendations
    ×
  • Retire
    • Income Investing Guide
    • Retirement Articles
    ×
  • More
    • Money Morning LIVE
    • Special Investing Reports
    • Our ELetters
    • Our Premium Services
    • Videos
    • Meet Our Experts
    • Profit Academy
    ×
  • Subscribe
Enter stock ticker or keyword
×
5 Ways to Beat the Fed (and Crush Inflation)

Email this Article

Send with mail | ahoo instead.
Required Needs to be a valid email
Required Needs to be a valid email
RGEN - Money Morning
https://moneymorning.com/stocks/rgen/
Required Please enter the correct value.
Twitter
RGEN

Repligen Cp

Biotechnology

Profit on This Biotech-Enabler That’s Suddenly a “Buy”

August 11, 2020 by William Patalon III

Start the conversation

Comment on This Story Click here to cancel reply.

Or to contact Money Morning Customer Service, click here.

Your email address will not be published. Required fields are marked *

Some HTML is OK

"Lead, follow, or get out of the way."

This is one of those well-known aphorisms that's been around forever – though its originator is unknown.

Truth be told, it doesn't matter who said it first. It's a great bit of advice.

Especially as we interpret it.

In our investment work here at Money Morning, we always seek to lead Wall Street and the rest of the packrat investment crowd.

We never follow, especially since "the crowd" tends to be indecisive, late to the gun – or flat out wrong.

And we always get out of the way – sidestepping the dust-rising thump that's an inevitable result of the miscues and sins of the Wall Street Goliath.

It's a simple formula. And a successful one.

And it's the reason we keep outperforming "the crowd."

Like the 2,067% gain on biotech Galapagos NV, the very first stock I recommended on the very first day I published my Member-based service, Private Briefing, back in August 2011.

My readers also pulled down peak gains of more than 2,892% in Nvidia, 2,828% in Advanced Micro Devices, 818% in biotech buyout Pharmacyclics, and more.

Today, I've decided to share my latest insight on one of my big biotech winners with Money Morning readers because the opportunity is too good to keep to ourselves. And since my colleague Michael Robinson recently talked about 2020's record-crushing biotech IPOs, it's the perfect time to share this.

The company I'm showing you today is essential to biotech stocks. It's a "biotech-enabler" that's zoomed 1,755% since I first told my readers about it back in June 2013.

In 2013, it was trading at $8.14.

It closed July 30 at $151.25 – not long after Investor's Business Daily said the stock had entered a "Buy Zone."

True, but where were they seven years and 1,755% ago?

Of course, what's important now is what comes next – and it's clear this stock's run isn't over… Full Story

Stocks

Our 3 Favorite Biotech Stocks to Play the Potential $727 Billion Biotech Market

May 15, 2018 by Money Morning Staff Reports

Start the conversation

Comment on This Story Click here to cancel reply.

Or to contact Money Morning Customer Service, click here.

Your email address will not be published. Required fields are marked *

Some HTML is OK

Biotech stocks have already netted investors huge gains.

In fact, we expect prices to skyrocket even further as the industry becomes a $727 billion juggernaut.

And we have three companies you need to know about before the industry closes in on $1 trillion right here...

LIVE
Visit Money Morning Live
Latest News

January 19, 2023 • By Money Morning Stock Research Team

These Stocks Could Go To $0

January 9, 2023 • By Money Morning Stock Research Team

The Government Is Pouring $391 Billion Into These Stocks - Buy Now

December 27, 2022 • By Money Morning Staff Reports

6 IPOs in 2023 You Can’t Afford to Miss
Trending Stories
ABOUT MONEY MORNING

Money Morning gives you access to a team of market experts with more than 250 years of combined investing experience – for free. Our experts – who have appeared on FOXBusiness, CNBC, NPR, and BloombergTV – deliver daily investing tips and stock picks, provide analysis with actions to take, and answer your biggest market questions. Our goal is to help our millions of e-newsletter subscribers and Moneymorning.com visitors become smarter, more confident investors.

QUICK LINKS
About Us COVID-19 Announcements How Money Morning Works FAQs Contact Us Search Article Archive Forgot Username/Password Archives Profit Academy Research Your Team Videos Text Messaging Terms of Use
FREE NEWSLETTERS
Total Wealth Research Power Profit Trades Profit Takeover This Is VWAP Penny Hawk Trading Today Midday Momentum Pump Up the Close
PREMIUM SERVICES
Money Map Press Home Money Map Report Fast Fortune Club Weekly Cash Clock Night Trader Microcurrency Trader Hyperdrive Portfolio Rocket Wealth Initiative Extreme Profit Hunters Profit Revolution Warlock's World Penny Nation Quantum Data Profits Live Trading Alliance Trade The Close Inside Money Trader Expiration Trader Vega Burst Trader Flashpoint Trader Darknet Hyper Momentum Trader

© 2023 Money Morning All Rights Reserved. Protected by copyright of the United States and international treaties. Any reproduction, copying, or redistribution (electronic or otherwise, including the world wide web), of content from this webpage, in whole or in part, is strictly prohibited without the express written permission of Money Morning.

Address: 1125 N Charles St. | Baltimore, MD, 21201 | USA | Phone: 888.384.8339 | Disclaimer | Sitemap | Privacy Policy | Whitelist Us | Do Not Sell My Info